The company's MYO technology uses a DNA blueprint and antibody factory to develop antibody therapeutics that can treat rare diseases, viral infections, autoimmune diseases, and more. RenBio's antibody delivery system is compatible with any antibody and serves as a platform technology that can be used for numerous therapeutic indications. The company aims to revolutionize the state of antibody therapeutics by overcoming the current manufacturing and delivery challenges of standard therapies. RenBio was co-founded by David D. Ho, MD, and Yaoxing Huang, PhD, and is backed by the Bill & Melinda Gates Foundation, DARPA, and private investors.